Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Sep;47:1795–1800.

Current management of acute ischemic stroke. Part 2: Antithrombotics, neuroprotectives, and stroke units.

A M Herd 1
PMCID: PMC2018571  PMID: 11570305

Abstract

OBJECTIVE: To help family physicians who care for patients with acute stroke or who are involved in planning service delivery or resource allocation to understand recent developments in acute stroke care. QUALITY OF EVIDENCE: A MEDLINE search indicated that most data were derived from well designed, randomized, double-blind, placebo-controlled trials, including all the largest international studies and large systematic reviews. MAIN MESSAGE: Routine anticoagulation is not recommended except for circumstances such as cardioembolic stroke or deep vein thrombosis prophylaxis. Antiplatelet therapy with low-dose acetylsalicylic acid (or another antiplatelet agent if ASA is contraindicated) should be initiated within 48 hours of stroke onset, although benefit is modest. Dedicated care for stroke patients reduces morbidity and mortality and can be cost effective. Recent research into defibrinogenating and neuroprotective agents suggests some benefit, although none are currently licensed for use. Combination therapy might be the answer. CONCLUSION: Management of acute stroke is an emerging discipline; many potential therapies are still experimental.

Full Text

The Full Text of this article is available as a PDF (159.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark C. M., Ewbank D., Lerner A., Doody R., Henderson V. W., Panisset M., Morris J. C., Fillenbaum G. G., Heyman A. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1997 Jul;49(1):70–75. doi: 10.1212/wnl.49.1.70. [DOI] [PubMed] [Google Scholar]
  2. Easton J. D. What have we learned from recent antiplatelet trials? Neurology. 1998 Sep;51(3 Suppl 3):S36–S38. doi: 10.1212/wnl.51.3_suppl_3.s36. [DOI] [PubMed] [Google Scholar]
  3. Forbes C. D. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Int J Clin Pract. 1997 Jun;51(4):205–208. [PubMed] [Google Scholar]
  4. Hankey G. J. Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop. Med J Aust. 1998 Nov 16;169(10):534–536. doi: 10.5694/j.1326-5377.1998.tb123401.x. [DOI] [PubMed] [Google Scholar]
  5. Hankey G. J., Warlow C. P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999 Oct 23;354(9188):1457–1463. doi: 10.1016/S0140-6736(99)04407-4. [DOI] [PubMed] [Google Scholar]
  6. Hass W. K., Easton J. D., Adams H. P., Jr, Pryse-Phillips W., Molony B. A., Anderson S., Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989 Aug 24;321(8):501–507. doi: 10.1056/NEJM198908243210804. [DOI] [PubMed] [Google Scholar]
  7. Hennerici M. Improving the outcome of acute stroke management. Hosp Med. 1999 Jan;60(1):44–49. doi: 10.12968/hosp.1999.60.1.1025. [DOI] [PubMed] [Google Scholar]
  8. Hickenbottom S. L., Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18(4):485–492. doi: 10.1055/s-2008-1040901. [DOI] [PubMed] [Google Scholar]
  9. Johnston K. C., Li J. Y., Lyden P. D., Hanson S. K., Feasby T. E., Adams R. J., Faught R. E., Jr, Haley E. C., Jr Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke. 1998 Feb;29(2):447–453. doi: 10.1161/01.str.29.2.447. [DOI] [PubMed] [Google Scholar]
  10. Kay R., Wong K. S., Yu Y. L., Chan Y. W., Tsoi T. H., Ahuja A. T., Chan F. L., Fong K. Y., Law C. B., Wong A. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1588–1593. doi: 10.1056/NEJM199512143332402. [DOI] [PubMed] [Google Scholar]
  11. Langhorne P. Developing comprehensive stroke services: an evidence-based approach. Postgrad Med J. 1995 Dec;71(842):733–737. doi: 10.1136/pgmj.71.842.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Langhorne P., Williams B. O., Gilchrist W., Howie K. Do stroke units save lives? Lancet. 1993 Aug 14;342(8868):395–398. doi: 10.1016/0140-6736(93)92813-9. [DOI] [PubMed] [Google Scholar]
  13. Lott C., Hennes H. J., Dick W. Stroke--a medical emergency. J Accid Emerg Med. 1999 Jan;16(1):2–7. doi: 10.1136/emj.16.1.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meschia J. F. Anticoagulant and defibrinogenating agents in acute ischemic stroke and cerebral venous thrombosis. Semin Neurol. 1998;18(4):461–470. doi: 10.1055/s-2008-1040899. [DOI] [PubMed] [Google Scholar]
  15. Phillis J. W. A "radical" view of cerebral ischemic injury. Prog Neurobiol. 1994 Mar;42(4):441–448. doi: 10.1016/0301-0082(94)90046-9. [DOI] [PubMed] [Google Scholar]
  16. Pushpangadan M., Wright J., Young J. Evidence-based guidelines for early stroke management. Hosp Med. 1999 Feb;60(2):105–114. doi: 10.12968/hosp.1999.60.2.1038. [DOI] [PubMed] [Google Scholar]
  17. Read S. J., Hirano T., Abbott D. F., Sachinidis J. I., Tochon-Danguy H. J., Chan J. G., Egan G. F., Scott A. M., Bladin C. F., McKay W. J. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology. 1998 Dec;51(6):1617–1621. doi: 10.1212/wnl.51.6.1617. [DOI] [PubMed] [Google Scholar]
  18. Roberts M., Hughes G. Recent advances in the acute management of ischaemic stroke. J Accid Emerg Med. 1999 Jan;16(1):7–12. doi: 10.1136/emj.16.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sandercock P. A., van den Belt A. G., Lindley R. I., Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):17–25. doi: 10.1136/jnnp.56.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Senior K. Taking the bite out of snake venoms. Lancet. 1999 Jun 5;353(9168):1946–1946. doi: 10.1016/S0140-6736(05)77162-2. [DOI] [PubMed] [Google Scholar]
  21. Sherman D. G., Atkinson R. P., Chippendale T., Levin K. A., Ng K., Futrell N., Hsu C. Y., Levy D. E. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000 May 10;283(18):2395–2403. doi: 10.1001/jama.283.18.2395. [DOI] [PubMed] [Google Scholar]
  22. Sherman D. G. Heparin and heparinoids in stroke. Neurology. 1998 Sep;51(3 Suppl 3):S56–S58. doi: 10.1212/wnl.51.3_suppl_3.s56. [DOI] [PubMed] [Google Scholar]
  23. Weitz J. I. Low-molecular-weight heparins. N Engl J Med. 1997 Sep 4;337(10):688–698. doi: 10.1056/NEJM199709043371007. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES